ESC 2022 Highlights: Recorded Webcast

This program will cover the key clinical trial findings and their implications from ESC 2022. This program is intended for cardiovascular specialists and primary care physicians from across Canada.

Discussion Topics:
- DELIVER – Does dapagliflozin improve outcomes in HFrEF?
- PERSPECTIVE – Does sacubitril/valsartan affect cognitive function in heart failure?
- PACIFIC Trials – What is the role of new factor Xa inhibitors in stroke and ACS?
- FOURIER OLE – What are the long-term safety data for PCSK9 inhibitors?
- ALL-HEART – Does allopurinol improve cardiovascular outcomes?
- SECURE – Is there a role for a polypill in secondary prevention?
- And more!

Learning Objectives:
Following participation in this program, participants will be able to:
- Identify the clinical implications of the new data presented at ESC 2022
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

Watch the recording on MDLearn Here
www.mdlearn.com > MDWatch